Prosecution Insights
Prosecution Insights
Tech Center 3700 • Art Units: 3763 3783 3791
This examiner grants 76% of resolved cases
Nilay J. Shah is an examiner in Tech Center 3700 and Art Unit 3763, with 608 resolved cases. The allowance rate is 76.3%, and the median days to allowance is 1154. The interview lift is a massive 46.9%, which is a very high value for this metric.
For the 608 cases processed, the 76.3% allowance rate and the 46.9% lift strongly suggest that interviews are the most effective way to secure a grant. The 1154-day median provides a clear expectation for the duration of the process. Practitioners should view the 46.9% lift as a critical strategic asset in Art Unit 3763. By engaging in direct dialogue, applicants can significantly improve their chances of success beyond the 76.3% baseline and potentially expedite the 1154-day median timeline.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18199752 | SYSTEMS AND METHODS FOR TREATING A STRICTURE ALONG THE BILIARY AND/OR PANCREATIC TRACT | Non-Final OA | Boston Scientific Scimed, Inc. |
| 18854188 | Deflectable Catheter Distal End | Non-Final OA | St. Jude Medical, Cardiology Division, Inc. |
| 18474753 | WIRE LOCK FOR MEDICAL DEVICES | Final Rejection | St. Jude Medical, Cardiology Division, Inc. |
| 18661199 | SEALING ARRANGEMENT FOR SYRINGE | Non-Final OA | AbbVie Inc. |
| 18491782 | MEDICAL DEVICE SYSTEM, AND DISPOSABLE CONTAINER | Final Rejection | Roche Diabetes Care, Inc. |
| 18700917 | Securement Systems for Vascular Devices | Non-Final OA | Solventum Intellectual Properties Company |
| 18293119 | CATHETER SECUREMENT DEVICE, KIT, AND METHOD OF USE THEREOF | Final Rejection | Solventum Intellectual Properties Company |
| 18046699 | INTRAVASCULAR DELIVERY SYSTEM AND METHOD FOR PERCUTANEOUS CORONARY INTERVENTION INCLUDING PERFUSION | Non-Final OA | VANTIS VASCULAR, INC. |
| 18547673 | GEOMETRICALLY DEFORMABLE IMPLANTABLE CONTAINMENT DEVICES FOR RETENTION OF BIOLOGICAL MOIETIES | Non-Final OA | W. L. Gore & Associates, Inc. |
| 18565890 | APPARATUS FOR FILLING A FLUID DELIVERY DEVICE | Final Rejection | Becton, Dickinson and Company |
| 18238613 | Extension Set Having Distally-Directed Extension Tube | Final Rejection | Becton, Dickinson and Company |
| 18364256 | CONTAINER FOR AN INJECTABLE MEDICAMENT | Non-Final OA | SANOFI |
| 18296088 | Drug Delivery Device | Final Rejection | Sanofi |
| 18671531 | MEDICAL DEVICE AND METHOD FOR LIMITING THE USE OF THE MEDICAL DEVICE | Non-Final OA | Sanofi-Aventis Deutschland GmbH |
| 18480258 | VARIABLE DUROMETER DILATOR FOR INTRAVASCULAR ACCESS DEVICES | Final Rejection | Cook Medical Technologies LLC |
| 18199638 | SWITCHING AND CUSTOMIZATION OF GLUCOSE PREDICTION MODELS IN MEDICAMENT DELIVERY DEVICES | Final Rejection | INSULET CORPORATION |
| 18851640 | SYSTEMS AND METHODS FOR THE TREATMENT OF CANCER USING ULTRASOUND | Non-Final OA | North Carolina State University |
| 18836906 | MEDICAMENT DELIVERY DEVICE | Non-Final OA | SHL Medical AG |
| 18711947 | A subassembly of a medicament delivery device | Non-Final OA | SHL Medical AG |
| 18700835 | A medicament container carrier of a medicament delivery device and a method of assembling a medicament delivery device medicament container assembly | Non-Final OA | SHL Medical AG |
| 18603010 | Autoinjector for Automatic Injection of a Product Into an Injection Site | Non-Final OA | Becton Dickinson France |
| 18530780 | Automatic Medical Injection Device | Final Rejection | Becton Dickinson France |
| 18853453 | CAPACITIVE SENSOR ASSEMBLY | Non-Final OA | Coloplast A/S |
| 18705290 | AUTOINJECTOR | Non-Final OA | medmix Switzerland AG |
| 18362007 | BALLOON DILATATION CATHETER AND ANGIOPLASTY USING THE SAME | Final Rejection | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18288676 | VARIABLE DOSE THERAPEUTIC AGENT DISPENSER | Final Rejection | NEUROCHASE TECHNOLOGIES LIMITED |
| 18149649 | METHODS FOR DELIVERY OF THERAPEUTIC MATERIALS TO TREAT CANCER | Final Rejection | RenovoRx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy